acebutolol and Osteomalacia

acebutolol has been researched along with Osteomalacia in 6 studies

Research

Studies (6)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (33.33)	24.3611
2020's	4 (66.67)	2.80

Authors

Authors	Studies
Schaefer, B; Wolf, M; Zoller, H	1
Bernal, L; Gutiérrez Casbas, A; Madero Velázquez, L; Muñoz Pérez, R; Orts, B; Rodríguez, A; Sempere, L	1
Amarnani, R; Javaid, MK; Travis, S	1
Ganz, T; Goodnough, LT; Kalantar-Zadeh, K; Levine, MA; Seid, MH; Trumbo, H	1
Glodny, B; Schaefer, B; Zoller, H	1
Asaad, S; Econs, M; Klein, K; Rubin, JE	1

Reviews

1 review(s) available for acebutolol and Osteomalacia

Article	Year
Parenteral iron therapy and phosphorus homeostasis: A review. American journal of hematology, 2021, 05-01, Volume: 96, Issue:5 Topics: Anemia, Hypochromic; Calcitriol; Ferric Compounds; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Homeostasis; Humans; Hypophosphatemia; Infusions, Parenteral; Iron; Iron Deficiencies; Kidney; Malabsorption Syndromes; Maltose; Osteomalacia; Parathyroid Hormone; Phosphorus; Phosphorus, Dietary	2021

Article

Year

Parenteral iron therapy and phosphorus homeostasis: A review.

American journal of hematology, 2021, 05-01, Volume: 96, Issue:5

Topics: Anemia, Hypochromic; Calcitriol; Ferric Compounds; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Homeostasis; Humans; Hypophosphatemia; Infusions, Parenteral; Iron; Iron Deficiencies; Kidney; Malabsorption Syndromes; Maltose; Osteomalacia; Parathyroid Hormone; Phosphorus; Phosphorus, Dietary

2021

Other Studies

5 other study(ies) available for acebutolol and Osteomalacia

Article	Year
Risk Factors for and Effects of Persistent and Severe Hypophosphatemia Following Ferric Carboxymaltose. The Journal of clinical endocrinology and metabolism, 2022, 03-24, Volume: 107, Issue:4 Topics: Alkaline Phosphatase; Anemia, Iron-Deficiency; Biomarkers; Calcium; Disaccharides; Familial Hypophosphatemic Rickets; Female; Ferric Compounds; Humans; Hypophosphatemia; Iron; Male; Maltose; Minerals; Osteomalacia; Parathyroid Hormone; Risk Factors	2022
Hypophosphatemic osteomalacia, a side effect of iron carboxymaltose administration. Revista espanola de enfermedades digestivas, 2022, Volume: 114, Issue:6 Topics: Ferric Compounds; Humans; Hypophosphatemia; Iron; Maltose; Osteomalacia	2022
Novel use of burosumab in refractory iron-induced FGF23-mediated hypophosphataemic osteomalacia. Rheumatology (Oxford, England), 2020, 08-01, Volume: 59, Issue:8 Topics: Adult; Anemia, Iron-Deficiency; Antibodies, Monoclonal, Humanized; Ferric Compounds; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Hypophosphatemia; Male; Maltose; Osteomalacia; Treatment Outcome	2020
Blood and Bone Loser. Gastroenterology, 2017, Volume: 152, Issue:6 Topics: Administration, Intravenous; Anti-Inflammatory Agents; Biopsy; Crohn Disease; Digestive System Surgical Procedures; Drug Therapy, Combination; Femoral Neck Fractures; Ferric Compounds; Gastrointestinal Agents; Hematinics; Humans; Hypophosphatemia; Hypophosphatemia, Familial; Magnetic Resonance Imaging; Male; Maltose; Middle Aged; Osteomalacia; Postoperative Hemorrhage	2017
Severe FGF23-based hypophosphataemic osteomalacia due to ferric carboxymaltose administration. BMJ case reports, 2018, Jan-03, Volume: 2018 Topics: Administration, Intravenous; Anemia, Iron-Deficiency; Crohn Disease; Diagnosis, Differential; Ferric Compounds; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Hypophosphatemia; Male; Maltose; Middle Aged; Osteomalacia; Phosphates; Treatment Outcome	2018